S. Jones

发表

Ibrutinib-associated ventricular arrhythmia in the FDA Adverse Event Reporting System

Connie Cheng, Afrouz Nayernama, D. Woronow, 2018, Leukemia & lymphoma.

Teriparatide-associated calciphylaxis: a case series

S. Jones, K. Konkel, M. Reyes, 2021, Osteoporosis International.

Unusual Neisseria species as a cause of infection in patients taking eculizumab.

P. Waldron, L. McNamara, Page E. Crew, 2019, The Journal of infection.

Repeated or Continuous Medically Supervised Ketamine Administration Associated with Hepatobiliary Adverse Events: A Retrospective Case Series

M. Mundkur, J. Wong, M. Avigan, 2021, Drug Safety.

Proteasome inhibitor‐associated thrombotic microangiopathy: A review of cases reported to the FDA adverse event reporting system and published in the literature

P. Waldron, B. Kanapuru, Afrouz Nayernama, 2020, American journal of hematology.

Use of an active surveillance system by the FDA to observe patterns of quinine sulfate use and adverse hematologic outcomes in CMS Medicare data

M. Reichman, T. MaCurdy, D. Graham, 2014, Pharmacoepidemiology and drug safety.

Postmarketing Colitis Cases Associated With Alpelisib Use Reported to the US Food and Drug Administration.

Tatiana M. Prowell, G. Dores, Kathleen M Sullivan, 2022, JAMA Oncology.

Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus

A. Brinker, S. Jones, S. Bersoff-Matcha, 2017, Annals of Internal Medicine.

Harmful effects of chlorine dioxide exposure

S. Jones, Carmen Cheng, Allison Lardieri, 2020, Clinical toxicology.

Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System

Tamra E. Meyer, A. Brinker, A. Ajao, 2017, Annals of Internal Medicine.

US‐based emergency department visits for fluoroquinolone‐associated hypersensitivity reactions

D. Budnitz, H. Mehta, A. Sorbello, 2013, Pharmacoepidemiology and drug safety.

Fluoroquinolone-Associated Myasthenia Gravis Exacerbation

Alfred Sorbello, S Christopher Jones, Robert M Boucher, 2011, Drug safety.

Postmarketing Cases of Enfortumab Vedotin-Associated Skin Reactions Reported as Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis.

S. Jones, M. Reyes, Michelle Nadeau Nguyen, 2021, JAMA dermatology.

Disseminated gonococcal infections in patients receiving eculizumab: a case series.

R. Kirkcaldy, K. Bernstein, P. Waldron, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Pentosan associated retinal pigmentary changes: FDA’s perspective on an emerging postmarketing safety finding

D. Moeny, A. Ajao, S. Jones, 2021, International Urogynecology Journal.

Systemic Adverse Events Associated with Compounded Topical Pain Products

S. Jones, J. Kim, K. Konkel, 2020, Drug Safety.

BCR‐ABL1 tyrosine kinase inhibitor‐associated thyroid dysfunction: A review of cases reported to the FDA Adverse Event Reporting System and published in the literature

P. Waldron, R. A. de Claro, Afrouz Nayernama, 2020, American journal of hematology.

Arterial aneurysm and dissection with systemic vascular endothelial growth factor inhibitors: A review of cases reported to the FDA Adverse Event Reporting System and published in the literature

L. Amiri-Kordestani, Connie Cheng, Afrouz Nayernama, 2021, Vascular medicine.

Hemolytic anemia following alectinib reported to the U.S. Food and Drug Administration Adverse Event Reporting System

G. Dores, Connie Cheng, Afrouz Nayernama, 2022, American journal of hematology.

An Evaluation of Postmarketing Reports of Serious Idiosyncratic Liver Injury Associated with Ulipristal Acetate for the Treatment of Uterine Fibroids

M. Avigan, A. Brinker, S. Jones, 2020, Drug Safety.

Etonogestrel implant migration to the vasculature, chest wall, and distant body sites: cases from a pharmacovigilance database.

A. Brinker, S. Jones, A. Niak, 2017, Contraception.

Emergency use authorization for intravenous peramivir: evaluation of safety in the treatment of hospitalized patients infected with 2009 H1N1 influenza A virus.

G. D. Dal Pan, H. Francis, K. Struble, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Injection-Site Nodules Associated With the Use of Exenatide Extended-Release Reported to the U.S. Food and Drug Administration Adverse Event Reporting System

A. Brinker, S. Jones, A. Niak, 2015, Diabetes Spectrum.

An Evaluation of Postmarketing Reports with an Outcome of Death in the US FDA Adverse Event Reporting System

G. D. Dal Pan, C. Kortepeter, M. Muñoz, 2020, Drug Safety.

Antibiotic prophylaxis in vaccinated eculizumab recipients who developed meningococcal disease: Antibiotic prophylaxis and eculizumab.

P. Waldron, L. McNamara, Page E. Crew, 2019, The Journal of infection.

Postmarketing Surveillance of Drug-Induced Liver Injury

A. Brinker, C. Kortepeter, S. Jones, 2018 .

Relative Thromboembolic Risks Associated with COX-2 Inhibitors

S. Jones, S. Jones, 2005, The Annals of pharmacotherapy.

Emergency use authorization for intravenous peramivir: evaluation of safety in the treatment of hospitalized patients infected with 2009 H1N1 influenza A virus.

G. D. Dal Pan, H. Francis, K. Struble, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.